Skip to main content

textochbilcontainer

A BUSINESS MODEL WITH FASTER TIME TO MARKET AND LOWER DEVELOPMENT RISK COMPARED WITH CONVENTIONAL DRUG DEVELOPMENT

textochbilcontainer

OUR CLINICAL pipeline CONSISTS of late stage drug candidates with a combined peak sales potential estimated at USD 350–700

textochbilcontainer

IN 2019/2020, the TWO PHASE 3 STUDIES FOR MOB-015 ARE BEING FINALIZED, all while commercialization plans are progressing with two license agreements in plaCe.  

textochbilcontainer

Moberg pharma’s operations are fully financed, aiming at making MOB-015 the future market leader in nail fungus (onychomycosis).

textochbilcontainer

We donate money to The Swedish Childhood Cancer Foundation

Moberg Pharma is a rapidly growing Swedish pharmaceutical company commercializing proprietary, acquired and licensed products in the global market. Initially, the company specialized in the treatment of skin diseases, with a focus on treatments for nail fungus. On March 29, 2019, the company divested its OTC Business, see press release

Stockvalue 2013-05-20 14:00
32,90 kr
+2,5 %

Subscribe

Get our latest press releases and reports

 

Calendar/presentations

Next calendar event: 2019-10-30 General Shareholders Meeting

Redemption of shares

In November 2019, a distribution of approximately 43-45 SEK per share is
planned through a redemption of shares

Mycological cure rate after MOB-015 treatment

...